GPC3 and cancer: For instance, higher expression of CD69, BTG2, MMP14, PCDH7, GPC3, and NMUR1 has been related to greater cancer cell drug sensitivity to a variety of chemotherapeutic agents, including oxaliplatin, vemurafenib, trametinib, paclitaxel, and vinblastine, etc. In contrast, elevated expression of IL7R and CCL20 was linked to greater cancer cell drug resistance to bosutinib, lapatinib, tamoxifen, IPI−145, and idelalisib.